Recent Achievements

  • On April 4, 2014 Medifocus announced Medifocus, Inc. to Be Featured on BNN & Fox Business News Network on April 6, 2014
    BNN to Air at 9:30 AM & 8:00 PM EDT; Fox Business to Air at 5:30 PM EDT.
  • On March 17, 2014 Medifocus announced that it is expanding its reach into the Asia Pacific market with the engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC.
  • On March 12, 2014 Medifocus announced that it was making a clinical presentation at the 24th Annual Interdisciplinary Breast Center Conference.
  • On March 11, 2014 Medifocus announced that the company completed a $2 Million Second Tranche Closing of $6 Million Convertible Debenture Financing.
  • On March 6, 2014 Medifocus announced its financial results for the third fiscal quarter and nine months ending December 31, 2013.
  • On March 6, 2014 Medifocus announced it obtained a newly allowed European Patent Office EPO patent.
  • On December 11, 2013 Medifocus announced VM Medical Center in Montreal has successfully treated its first patient.
  • On December 4, 2013 Medifocus announced a record 294% increase in Q2/FY 2014 revenue.
  • On November 12, 2013 Medifocus announced a joint venture with Ideal Concept Group, Ltd.
  • On August 29, 2013 Medifocus announced its financial results for its first fiscal quarter of 2014 ended June 30, 2013.
  • On August 9, 2013 Medifocus announced that it has initiated its Principal Investigational Site at VM Medical in Montreal, Canada for its APA-1000 Focused Microwave Breast Thermotherapy System Pivotal Phase III clinical study. The VM Medical Center is the largest non-public private breast center in Canada.

  • On July 31, 2013 Medifocus announced it has obtained a newly allowed patent, which, together with several other patents already issued to Medifocus, has the potential to significantly broaden the clinical applications of the targeted thermotherapy systems and devices developed based on the Company‚Äôs two proprietary technology platforms.
  • On July 24, 2013 Medifocus announced that it has filed its financial statements for the year ended March 31, 2013.
  • On July 24, 2013 Medifocus announced that it has enlisted the services of Maxim Group LLC, a leading investment banking, securities and investment management firm, to provide strategic corporate finance and investment banking services.
  • On July 25, 2012 Medifocus announced that it had completed the purchase of all Prolieve (R) assests from Boston Scientific Corporation. Prolieve is FDA approved for the treatment of Benign Prostatic Hyperplasia (BPH).